About this episode

The episode discusses model-informed precision dosing and its application in individualized dosing decisions.

In this episode of Communicable , Amy Legg (Brisbane, Australia), Rekha Pai Mangalore (Melbourne, Australia) & Angela Huttner (Geneva, Switzerland) return for the third part of the ‘We will make you love PK/PD’ series. The hosts are joined by two experts, Amanda Gwee (Melbourne, Australia) & Sebastian Wicha (Hamburg, Germany), to dive into an important application of PK/PD: model-informed precision dosing (MIPD), and how it allows for more informed, individualised dosing decisions. The episode also covers the open-access educational tools, KidsCalc and TDMx, developed by Gwee and Wicha respectively, and the steps clinicians can take to put MIPD into practice, keeping the individual patient at the centre of dosing decisions. Resources TDMx, https://www.tdmx.eu/ KidsCalc, https://www.kidscalc.org/ Further reading Broeker A, et al. Towards precision dosing of vancomycin: a systematic evaluation of pharmacometric models for Bayesian forecasting. CMI 2019. DOI: 10.1016/j.cmi.2019.02.029 Brusamarello C, et al. How important are MIC determination methods when targeting vancomycin levels in patients with Staphylococcus aureus infections? J Antimicrob Chemother 2021. DOI…

People in this episode

Hosts: Amy Legg, Rekha Pai Mangalore, Angela Huttner

Guests: Amanda Gwee, Sebastian Wicha

Topics covered

• PK/PD
• model-informed precision dosing
• individualized dosing
• clinical practice
• educational tools

Keywords

• PK/PD
• precision dosing
• MIPD
• KidsCalc
• TDMx
• clinical dosing
• pharmacometric models

Mentioned in this episode

Organizations: CMI Communications

Products: KidsCalc, TDMx

Books & works: Towards precision dosing of vancomycin: a systematic evaluation of pharmacometric models for Bayesian forecasting, How important are MIC determination methods when targeting vancomycin levels in patients with Staphylococcus aureus infections?, Bedside model-informed precision dosing of vancomycin in severely ill neonates and children in Belgium (the BENEFICIAL trial): a multicentre, randomised controlled trial

Places: Brisbane, Australia, Melbourne, Australia, Geneva, Switzerland, Hamburg, Germany

More episodes of Communicable

• Communicable E62: The 'prose' and cons of the POET trial – early oral antibiotic switch for endocarditis · September 6, 2026 · 52 min
• Communicable E60: Quarterly catch-up (August 2026 edition) · August 9, 2026 · 49 min
• Communicable E59: 'Ask me anything' – EUCAST and CLSI leadership explain · July 26, 2026 · 1h 9m
• Communicable E58: Reducing hospital-acquired pneumonia – the HAPPEN trial and how it happened · July 12, 2026 · 54 min
• Communicable E57: We will make you love PK/PD, part 2 · June 28, 2026 · 47 min
• Communicable E56: Frequentist vs Bayesian for clinical trial analysis – 99% probability you’ll want to listen to this · June 14, 2026 · 1h 5m

Explore listener stats, chart rankings, contacts and more on the Communicable podcast page.